
OpenClaw, an open-source AI agent, has launched its app on Android and iOS, making it accessible on mobile devices. Users can now connect their phones to the OpenClaw Gateway, enabling them to run AI agents for various tasks directly from their pockets. This development follows OpenClaw's viral success earlier this year and reflects the increasing integration of AI agents into daily technology use. Despite mixed results reported by users, the app's release signifies a step forward in the accessibility of AI-driven automation.
Read originalEarlier coverage that leads up to this article, and what followed. Lines connect each piece to the closest one after it, converging here.
© TechCrunch AIxAI's attempt to dismiss the NAACP's Clean Air Act lawsuit failed after a federal judge ruled that its gas turbines are not exempt mobile sources and that plaintiffs have standing. This legal setback confirms that AI infrastructure operators cannot bypass environmental permitting by classifying heavy industrial equipment as temporary or mobile. The ruling forces xAI to face scrutiny over air quality impacts at its Colossus data center, setting a precedent for how large-scale compute facilities are regulated under existing environmental laws.
© TechCrunch AILev Selector · March 6, 2026 · Related
Lev Selector · March 20, 2026 · Related
NVIDIA Blog · April 30, 2026 · Same story
Matt Wolfe · May 6, 2026 · Related
TechCrunch AI · May 19, 2026 · Related
WIRED AI · May 20, 2026 · Related
WIRED AI · May 26, 2026 · Related
The Verge AI · June 2, 2026 · Related
The AI Daily Brief · August 13, 2026 · Related
The AI Daily Brief · September 2, 2026 · Related
OpenAI · September 10, 2026 · Related
TechCrunch AI · September 22, 2026 · Related
The Verge AI · September 29, 2026 · Related
OpenAI is scaling back its ambitions as investor appetite for massive AI infrastructure bets cools. The company has lowered its fundraising target from $30 billion to $20 billion, with only $11 billion secured so far against a valuation that has dropped from $1.4 trillion. This retreat signals a growing wariness among Wall Street investors regarding the capital intensity of the AI race, forcing even the most dominant players to adjust their financial expectations.
Exin Therapeutics has demonstrated an AI agent physically controlling a robotic arm to inject drugs into a live mouse's brain. The experiment reveals a critical divergence in model behavior: Anthropic’s Claude Opus refused the procedure due to safety concerns, while Sonnet proceeded. This suggests that as agents gain direct access to physical lab equipment, their alignment and refusal mechanisms become operational realities rather than theoretical safeguards. It marks a shift from AI merely analyzing data to actively manipulating biological systems under human supervision. The team initially tested Claude Opus 5.5, but it halted the injection, citing potential harm. Switching to Claude Sonnet 5 allowed the procedure to complete, though with delays caused by coordinate system glitches. A secondary Opus agent had to fix code errors without knowing a live surgery was underway. Human oversight remains essential as researchers test more complex tasks like craniotomies.